ProShares - Ultra MSCI Japan
EZJ News Today: Stay Updated with the Latest ProShares - Ultra MSCI Japan News in Real Time
Find EZJ news now at Meyka AI. Stay informed with the latest ProShares - Ultra MSCI Japan stocks updates, including price news, market analysis, and expert insights.
Japan Homeownership Debate, April 09: Mortgage Risk Fears Rise
Japan homeownership risk debate intensifies as rate worries, cost inflation, and dual‑income stress drive refinancing and used-home demand. What borrowers and investors in JP should watch now.
SMMT Upgraded to Buy by Citigroup on April 08, 2026
Citigroup initiates coverage of Summit Therapeutics (SMMT) with Buy rating, citing scarcity value in competitive drug development landscape.
SMMT Analyst Rating: Citigroup Initiates Buy Coverage April 2026
Citigroup initiates Buy coverage on Summit Therapeutics (SMMT) with initial analyst rating, citing scarcity value in competitive drug market.
SMMT Analyst Rating: Citigroup Initiates Buy Coverage April 2026
Citigroup initiates Buy coverage on Summit Therapeutics (SMMT) with initial analyst rating, citing scarcity value in competitive drug market.
SMMT Analyst Rating: Citigroup Initiates Buy Coverage April 2026
Citigroup initiates Buy rating on Summit Therapeutics (SMMT) on April 8, 2026, citing scarcity value in competitive drug development landscape.
9236.T Japan M&A Solution (JPX) +26.81% after hours 09 Apr 2026: watch price targets
After-hours mover 9236.T stock hits JPY 1367.00; analysis, Meyka grade and price forecast
RYAAY Stock Today: April 9 Europe Flight Cancellations Hit Carriers
Flight cancellations across Europe are pressuring airlines like Ryanair, easyJet, and Air France-KLM. See how costs, EU261 compensation, and Q2 margins may impact RYAAY for Canadian investors.
Japan’s Shiden-Kai Raised April 09: Restoration Plan, Tourism Upside
Shiden-Kai salvage off Akune, Kagoshima on April 9: restoration plan, legal steps, tourism upside, and funding paths for museums and sponsors in Japan.
4506.T Stock Today: April 9 – ¥116.5B Public Offering for R&D, Debt
Sumitomo Pharma public opening: up to ¥116.49B via 51.3M new shares plus 7.70M OA. Key dates Apr 20–30, dilution math, use of funds, and trading takeaways for Japan investors.